Rossari Biotech Reports Record Sales Amid Declining Profitability in Q3 FY24-25

Rossari Biotech, a small-cap player in the chemicals industry, has reported its financial results for the third quarter of FY24-25, declared on January 21, 2025. The company has experienced an adjustment in its evaluation, with its financial score reflecting a notable shift.
In terms of sales, Rossari Biotech achieved its highest quarterly net sales at Rs 512.73 crore, demonstrating consistent growth over the last five quarters. However, the company's profitability metrics indicate challenges. Profit Before Tax (PBT), excluding other income, fell to Rs 41.83 crore, marking the lowest level in the last five quarters and showing a decline compared to the average PBT from the previous four quarters. Similarly, Profit After Tax (PAT) decreased to Rs 31.70 crore, also lower than the average PAT from prior periods.

Earnings per Share (EPS) reached Rs 5.73, reflecting a decline in profitability and earnings for shareholders. Furthermore, cash and cash equivalents were recorded at Rs 27.38 crore, the lowest in the last six half-yearly periods, which raises concerns about the company's short-term liquidity position.

For more insights on Rossari Biotech's financial trends and evaluation changes, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.